Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020
February 06 2020 - 8:30AM
Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the
“Company”), a biotechnology company developing potentially
disease-modifying AAV-based gene therapies for patients with
neurodegenerative diseases, today announced the upcoming
presentation of three abstracts at the 16th Annual WORLDSymposium™,
taking place February 10-13, 2020, in Orlando, FL. The
abstracts include preclinical data from Prevail’s programs PR001
for neuronopathic Gaucher disease and PR006 for frontotemporal
dementia with GRN mutation.
Two abstracts will be presented during the poster session on
Monday, February 10th from 4:30 p.m. to 6:30 p.m. ET. Poster
information is as follows:
Abstract Title: Gene therapy PR006 increased progranulin levels
and improved lysosomal related phenotypes in model systems (poster
#52)Presenter: Laura Heckman, Ph.D.
Abstract Title: Gene therapy PR001 increased GCase activity and
improved neuronopathic Gaucher disease phenotypes in mouse models
(poster #159)Presenter: Laura Heckman, Ph.D.
One abstract will be presented during the Contemporary Forum
session on Thursday, February 13th at 1:30 p.m. ET. Oral
presentation information is as follows:
Abstract Title: Gene therapy PR006 increased progranulin levels
and improved lysosomal related phenotypes in model systems
Presenter: Asa Abeliovich, M.D., Ph.D.
In addition to its presentations at WORLDSymposium, on
Wednesday, February 12th at 8:30 p.m. ET, management will be
hosting a presentation by Professor Ari Zimran, M.D., a key opinion
leader in the field of neuronopathic Gaucher disease, on “Unmet
Needs and Emerging Therapeutic Options for Neuronopathic Gaucher
Disease”, with a roundtable discussion to follow. A recording
of this event and accompanying slides will be made available
immediately following its conclusion and can be found under “Events
and Presentations” in the Investors & Media section of the
company's website, www.prevailtherapeutics.com. The webcasts will
be archived for 90 days following the presentation.
About Prevail Therapeutics Prevail is a gene
therapy company leveraging breakthroughs in human genetics with the
goal of developing and commercializing disease-modifying AAV-based
gene therapies for patients with neurodegenerative diseases. The
company is developing PR001 for patients with Parkinson’s disease
with a GBA1 mutation (PD-GBA) and neuronopathic Gaucher disease;
PR006 for patients with frontotemporal dementia with GRN mutation
(FTD-GRN); and PR004 for patients with certain
synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a
collaborative effort with The Silverstein Foundation for
Parkinson’s with GBA and OrbiMed, and is headquartered in New York,
NY.
Forward-Looking Statements Related to Prevail
Statements contained in this press release regarding matters that
are not historical facts are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Examples of these forward-looking statements
include statements concerning Prevail’s ability to develop
meaningful therapeutic advances for patients with neurodegenerative
diseases. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, among others: Prevail’s novel
approach to gene therapy makes it difficult to predict the time,
cost and potential success of product candidate development or
regulatory approval; Prevail’s gene therapy programs may not meet
safety and efficacy levels needed to support ongoing clinical
development or regulatory approval; the regulatory landscape for
gene therapy is rigorous, complex, uncertain and subject to change;
and the fact that gene therapies are novel, complex and difficult
to manufacture. These and other risks are described more fully in
Prevail’s filings with the Securities and Exchange Commission
(SEC), including the “Risk Factors” section of the Company’s
Quarterly Report on Form 10-Q for the period ended September 30,
2019, filed with the SEC on November 12, 2019, and its other
documents subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Prevail undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Media Contact:Katie Engleman1AB
katie@1ABmedia.com
Investor
Contact:investors@prevailtherapeutics.com
Prevail Therapeutics (NASDAQ:PRVL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prevail Therapeutics (NASDAQ:PRVL)
Historical Stock Chart
From Apr 2023 to Apr 2024